Opexa Therapeutics Inc (NASDAQ:OPXA)

CAPS Rating: 1 out of 5

A biopharmaceutical company developing autologous cellular therapies to treat several major illnesses, including multiple sclerosis, rheumatoid arthritis, diabetes, and cardiovascular disease.

Results 1 - 7 of 7

Recs

0
Member Avatar Allstar13913 (99.83) Submitted: 9/12/2014 11:14:52 PM : Underperform Start Price: $1.34 OPXA Score: +37.09

Uses known stock pump and dumper Redchip.com for PR purposes. Garbage.

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 11/15/2013 3:00:17 PM : Outperform Start Price: $2.29 OPXA Score: -76.17

One massive IHS on monhtly

Recs

1
Member Avatar whoodatstockhot (80.50) Submitted: 8/7/2013 1:07:06 PM : Outperform Start Price: $2.99 OPXA Score: -92.62

Cutting edge research being completed at Opexa, huge buyout potential here, one of those specs that could change how MS is treated. Balance sheet strong, low risk of secondary. Great risk reward, with over 500% upisde quite possible for long-term holders in 2014.

Recs

1
Member Avatar pugnaciously (27.55) Submitted: 11/14/2011 12:07:33 PM : Outperform Start Price: $5.44 OPXA Score: -148.84

Fast Track status just announced by the FDA for its multiple sclerosis drug, Tovaxin. It is currently in Stage IIb of clinical trials, thus far showing effectiveness where other drugs have failed. Namely treating SPMS - Secondary Progressive Multiple Sclerosis. It also is thus far effective in treating Relapsing Remitting MS. Thus, it's a potential double winner in combating the early and secondary form of the disease. “The TERMS trial was a landmark study in that it was the first time that a personalized immunotherapy of this nature was used to treat MS patients,” commented Edward Fox, MD, PhD, director of the MS Clinical of Central Texas, and a principal investigator in the TERMS study. “The results were encouraging in that they supported the continued development of Tovaxin in both relapsing remitting and secondary progressive MS.”

Recs

0
Member Avatar p1a5244 (50.18) Submitted: 9/11/2011 6:48:06 PM : Outperform Start Price: $5.00 OPXA Score: -163.39

Options Predictor Rank #18 on 9/11/11. P/C Ratio 0.029 and Call Sizzle 3.605.

Recs

0
Member Avatar izmoren (< 20) Submitted: 2/11/2011 4:22:04 PM : Outperform Start Price: $8.00 OPXA Score: -144.84

pb

Recs

0
Member Avatar dolphin77 (< 20) Submitted: 6/14/2010 12:52:36 PM : Outperform Start Price: $6.57 OPXA Score: -174.14

If they can sign a pharma partnership for Tovaxin the stock should trade a lot higher. Mkt cap is very cheap for a company with a safe and effective MS drug in late stage trials.

Results 1 - 7 of 7

Featured Broker Partners


Advertisement